In the Room Where it Happens
Drug discovery, financial AI, and materials science research — validated at the world's most selective technical conferences. Founded by a former META EVP and AI researcher since the 1990s.
Foundational architectures that transfer across disciplines — from molecular dynamics to regulatory compliance.
Integrates Bayesian Optimization with Generative AI and Causal Discovery to autonomously formulate, test, and refine scientific hypotheses. Reduces wet-lab iteration cycles by orders of magnitude.
Polyculture agent ensembles with built-in self-falsification and physics-informed surrogates. Every claim is verified against ground truth before propagation, eliminating hallucination cascades.
The same core methodology — validated independently in each domain with peer-reviewed results.
Accelerating drug discovery from target identification through lead optimization. ACHT-driven molecular generation with causal ADMET prediction.
Echo chamber detection, causal risk propagation, and verified portfolio construction. Separating signal from herding in markets.
Neuro-symbolic regulation models combining formal logic with LLM reasoning. Automated compliance verification with provenance tracking.
Physics-informed surrogates for crystal structure prediction, alloy optimization, and ceramic formulation with DFT-validated accuracy.
Selected papers from top-tier venues. Full list on the publications page.
Our research is validated at the same conferences where Google DeepMind, OpenAI, and leading university labs publish their breakthroughs.
Six platforms translating research into real-world impact — each validated against domain benchmarks.
End-to-end molecular generation with causal ADMET filtering and synthesis planning.
Multi-agent literature review, hypothesis generation, and experimental design.
Autonomous scientific discovery with formal verification and reproducibility guarantees.
Surrogate-accelerated ceramic formulation and firing profile optimization.
“Peer-Reviewed.
Production-Deployed.”
Every method is validated through peer review before deployment. We believe scientific acceleration requires institutional-grade rigour with the speed and focus of an independent research lab. Founded by a former META EVP. Revenue-generating across drug discovery and financial AI.
AIXC Research offers rare horizontal AI capabilities spanning drug discovery, financial markets, and materials science — backed by 50+ peer-reviewed papers at NeurIPS, AAAI & ICLR, 6 production-deployed platforms, and a team founded by a former META EVP. We welcome acquisition discussions, technology licensing, and strategic research partnerships.
Acquisition inquiries · Technology licensing · Joint research · Strategic investment
From molecular discovery to climate science — explore the platforms built on ACHT and VAP.
